ATM Kinase Dead: From Ataxia Telangiectasia Syndrome to Cancer
Overview
Authors
Affiliations
ATM is one of the principal players of the DNA damage response. This protein exerts its role in DNA repair during cell cycle replication, oxidative stress, and DNA damage from endogenous events or exogenous agents. When is activated, ATM phosphorylates multiple substrates that participate in DNA repair, through its phosphoinositide 3-kinase like domain at the 3'end of the protein. The absence of ATM is the cause of a rare autosomal recessive disorder called Ataxia Telangiectasia characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility, and radiation sensitivity. There is a correlation between the severity of the phenotype and the mutations, depending on the residual activity of the protein. The analysis of patient mutations and mouse models revealed that the presence of inactive ATM, named ATM kinase-dead, is more cancer prone and lethal than its absence. mutations fall into the whole gene sequence, and it is very difficult to predict the resulting effects, except for some frequent mutations. In this regard, is necessary to characterize the mutated protein to assess if it is stable and maintains some residual kinase activity. Moreover, the whole-genome sequencing of cancer patients with somatic or germline mutations has highlighted a high percentage of mutations in the phosphoinositide 3-kinase domain, mostly in cancer cells resistant to classical therapy. The relevant differences between the complete absence of ATM and the presence of the inactive form in in vitro and in vivo models need to be explored in more detail to predict cancer predisposition of A-T patients and to discover new therapies for ATM-associated cancer cells. In this review, we summarize the multiple discoveries from humans and mouse models on ATM mutations, focusing into the inactive versus null ATM.
Liang H, Fang C, Qiu M Sci Rep. 2025; 15(1):159.
PMID: 39747499 PMC: 11695685. DOI: 10.1038/s41598-024-83921-3.
Nakano Y, Kuiper R, Nichols K, Porter C, Lesmana H, Meade J Clin Cancer Res. 2024; 30(22):5009-5020.
PMID: 39264246 PMC: 11705613. DOI: 10.1158/1078-0432.CCR-24-1098.
Bajek A, Przewodowska D, Koziorowski D, Jedrzejowska M, Szlufik S Front Neurol. 2023; 14:1243535.
PMID: 37808486 PMC: 10556495. DOI: 10.3389/fneur.2023.1243535.
Karmokar A, Sargeant R, Hughes A, Baakza H, Wilson Z, Talbot S Cancers (Basel). 2023; 15(16).
PMID: 37627223 PMC: 10453052. DOI: 10.3390/cancers15164195.
Cancer Predisposition Syndromes and Thyroid Cancer: Keys for a Short Two-Way Street.
Balinisteanu I, Panzaru M, Caba L, Ungureanu M, Florea A, Grigore A Biomedicines. 2023; 11(8).
PMID: 37626640 PMC: 10452453. DOI: 10.3390/biomedicines11082143.